CoChat

A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer

Open access
Jafarnejad, Mohammad, Gong, Chang, Gabrielson, Edward, Bartelink, Imke H., Vicini, Paolo, Wang, Bing, Narwal, Rajesh, Roskos, Lorin, Popel, Aleksander S. · 2019 · The AAPS Journal
Cited by 62

The DOI matches its Crossref record; 15 of the 15 references it cites were found in a registry or an index.

Abstract

Immunotherapy and immune checkpoint blocking antibodies such as anti-PD-1 are approved and significantly improve the survival of advanced non-small cell lung cancer (NSCLC) patients, but there has been little success in identifying biomarkers capable of separating the responders from non-responders before the onset of the therapy. In this study, we developed a quantitative system pharmacology (QSP) model to represent the anti-tumor immune response in human NSCLC that integrated our knowledge of tumor growth, antigen processing and presentation, T cell activation and distribution, antibody pharmacokinetics, and immune checkpoint dynamics. The model was calibrated with the available data and was used to identify potential biomarkers as well as patient-specific response based on the patient parameters. The model predicted that in addition to tumor mutational burden (TMB), a known biomarker for anti-PD-1 therapy in NSCLC, the number of effector T cells and regulatory T cells in the tumor and blood is a predictor of the responders. Furthermore, the model simulated a set of 12 patients with known TMB and MHC/antigen-binding affinity from a recent clinical trial ( ClinicalTrials.gov number, NCT02259621) on neoadjuvant nivolumab therapy in resectable lung cancer and predicted an augmented durable response in patients with adjuvant nivolumab treatment in addition to the clinical trial protocol of neoadjuvant nivolumab treatment followed by resection. Overall, the model provides a valuable framework to model tumor immunity and response to immune checkpoint blockers to enhance biomarker discovery and performing virtual clinical trials to aid in design and interpretation of the current trials with fewer patients.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1208/s12248-019-0350-x

Cites

15 of 15 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 15 references

Cited by

See all 62

Metadata

Authors
Jafarnejad, M., Gong, C., Gabrielson, E., Bartelink, I. H., Vicini, P., Wang, B., Narwal, R., Roskos, L., & Popel, A. S.
Venue
The AAPS Journal
Published
2019-06-24
Volume
21
Issue
5
Pages
79-79
ISSN
1550-7416 (ISSN-L)
OpenAlex
W2949202427
Cited by
62
References
15
FWCI
3.08
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer. https://app.cochat.ai/papers/10.1208/s12248-019-0350-x
The paper
Jafarnejad, M., Gong, C., Gabrielson, E., Bartelink, I. H., Vicini, P., Wang, B., Narwal, R., Roskos, L., & Popel, A. S. (2019). A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer. The AAPS Journal. https://doi.org/10.1208/s12248-019-0350-x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.